Taking stock of the drug industry, from the lab to the medicine chestMarch 25, 2025Check out STAT+Sponsored By By Ed SilvermanPharmalot Columnist, Senior Writer Adobe STAT+ | Net prices for medicines inched up in last year's fourth quarter after falling a year ago, analysis finds Net prices are likely to decline this year due to the ongoing introduction of biosimilars, particularly for a class of medicines known as TNF. By Ed Silverman STAT+ | Health insurers' rapid adoption of AI tools is outpacing regulators' ability to keep watch "Companies are full steam ahead and regulators are behind," says one expert as the health insurance industry starts using AI in almost every aspect of care. By Casey Ross STAT+ | Opinion: Impatient about cell and gene therapy? Progress in biotech is not always linear Tim Hunt, CEO of the Alliance for Regenerative Medicine, explains "the incredibly promising but nonlinear world of cell and gene therapies." By Tim Hunt Justin Sullivan/Getty Images STAT+ | 23andMe's bankruptcy is the worst thing that could happen to just about everyone involved Co-founder Anne Wojcicki and shareholders are hurting, but customers whose data may not be protected are the worst off. By Matthew Herper Can philanthropy rescue struggling small biotechs? Today's biotech news includes discussion of whether philanthropies can help struggling biotechs and news of 23andMe's bankruptcy filing. By Meghana Keshavan More around STATCheck out more exclusive coverage with a STAT+ subscriptionRead premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.Enjoying Pharmalot? Tell us about your experienceContinue reading the latest health & science news with the STAT appDownload on the App Store or get it on Google Play STAT, 1 Exchange Place, Boston, MA©2025, All Rights Reserved.I no longer wish to receive STAT emailsUpdate Newsletter Preferences • Contact Us • Advertise with Us • View in Browser
Post Comment
No comments